Loading company…
Rigenerand develops regenerative medicine therapies for tissue repair and is based in Milan, Italy.
Founded in 2009 in Italy and headquartered in Milan, Rigenerand works on regenerative medicine and therapies aimed at tissue repair. In May 2022, Evotec SE acquired Rigenerand for EUR 23 million. The company reported revenue of EUR 5,423,507.80 and EBITDA of EUR 1,386,817.20 in fiscal 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in